{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:28:21Z","timestamp":1791520101201,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008016.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000}}],"reference-count":536,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008016.pub3","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T10:00:44Z","timestamp":1598349644000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Maintenance treatment with antipsychotic drugs for schizophrenia"],"prefix":"10.1002","volume":"2020","author":[{"given":"Anna","family":"Ceraso","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Section of Psychiatry; University of Brescia; Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie Jingxia","family":"LIN","sequence":"additional","affiliation":[{"name":"School of Nursing; The University of Hong Kong; Hong Kong SAR Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; School of Medicine, Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; School of Medicine, Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Tardy","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry (UPK); University of Basel; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[{"name":"Klinik Nord; M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; School of Medicine, Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Davis","sequence":"additional","affiliation":[{"name":"Maryland Psychiatric Research Center; Baltimore, MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; School of Medicine; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0001|cit1","first-page":"S419","article-title":"Long-term effects of aripiprazole on the lipid profiles of patients with schizophrenia in a 26-week placebo-controlled trial","volume":"33","author":"Baker","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008016.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S0924-977X(02)80404-7","article-title":"Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia","volume":"12","author":"Carson","year":"2002","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0003|cit3","unstructured":"Carson W Pigott T Saha A Ali M McQuade RD Torbeyns AF Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0004|cit4","first-page":"181","article-title":"Aripiprazole is not associated with increased diabetes risk: a long-term model","volume":"67","author":"Carson","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0005|cit5","unstructured":"Carson WH Ingenito GG McQuade RD Stock EG Iwamoto T Schizophrenia: safety\/tolerability of aripiprazole Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0006|cit6","first-page":"S187","article-title":"Aripiprazole vs placebo in the treatment of chronic schizophrenia","volume":"5","author":"Carson","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0920-9964(03)80440-1","article-title":"Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia","volume":"60","author":"Casey","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008016.pub3-BIB0008|cit8","first-page":"S417","article-title":"Long-term treatment with aripiprazole: effects on plasma lipis levels and glycaemic control","volume":"7","author":"Casey","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0009|cit9","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 1 http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0010|cit10","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 2 http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0011|cit11","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 3 http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0012|cit12","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 4 http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0013|cit13","unstructured":"Marder SR Kaplita S Saha AR Torbeyns A Stock EG Glycemic control and plasma lipids in long-term aripiprazole treatment Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0014|cit14","first-page":"S496","article-title":"Aripiprazole versus olanzapine in a 52-week, open-label extension study","volume":"31","author":"McQuade","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ebmh.7.2.41","article-title":"Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia","volume":"7","author":"Mortimer","year":"2004","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0017|cit17","unstructured":"Pigott TA Saha AR Ali MW McQuade RD Torbeyns AF William HC Aripiprazole versus placebo in the treatment of chronic schizophrenia Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/S0924-977X(03)92061-X","article-title":"Plasma lipids levels and glycemic control in long-term treatment with aripiprazole","volume":"13","author":"Stock","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0019|cit19","first-page":"192","article-title":"Glycemic control and plasma lipids in long-term treatment with aripiprazole","volume":"67","author":"Torbeyns","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0020|cit20","unstructured":"Correll C Kohegyi E Zhao C Baker RA McQuade R Salzman P Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia Neuropsychopharmacology 2014 S349 S350"},{"issue":"9","key":"10.1002\/14651858.CD008016.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaac.2017.06.013","article-title":"Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study","volume":"56","author":"Correll","year":"2017","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0022|cit22","unstructured":"A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01149655 2010"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0023|cit23","first-page":"111","article-title":"Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia","volume":"15","author":"Baker","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub3-BIB0024|cit24","first-page":"376","article-title":"Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia","volume":"18","author":"Baker","year":"2013","journal-title":"CNS Spectrums"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0025|cit25","first-page":"S321","article-title":"Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia","volume":"39","author":"Baker","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/S0920-9964(14)70830-8","article-title":"The effect of previous dose or oral aripiprazole (10 or 30 mg\/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials","volume":"153","author":"Baker","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0027|cit27","first-page":"112","article-title":"Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia","volume":"15","author":"Carson","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(13)77138-4","article-title":"A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia","volume":"28","author":"Eramo","year":"2013","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1016\/S0920-9964(14)70512-2","article-title":"All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials","volume":"153","author":"Eramo","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD008016.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.schres.2014.09.019","article-title":"Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies","volume":"159","author":"Fleischhacker","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD008016.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"A550","DOI":"10.1016\/j.jval.2013.08.1419","article-title":"Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia","volume":"16","author":"Fleischhacker","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0032|cit32","first-page":"171","article-title":"Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia","volume":"28","author":"Fleischhacker","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0033|cit33","first-page":"S394","article-title":"Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials","volume":"38","author":"Fleischhacker","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3371\/CSRP.KASA.022015","article-title":"Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies","volume":"9","author":"Kane","year":"2015","journal-title":"Clinical Schizophrenia and Related Psychoses"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0035|cit35","first-page":"S119","article-title":"Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia","volume":"15","author":"Kane","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(12)70503-5","article-title":"Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia","volume":"22","author":"Loze","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0038|cit38","unstructured":"Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia https:\/\/www.ClinicalTrials.gov\/ct\/show\/ 2008"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0039|cit39","first-page":"133","article-title":"Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia","volume":"15","author":"Sanchez","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/S0924-977X(12)70502-3","article-title":"A placebo-controlled study of efficacy\/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia","volume":"(Suppl 2)","author":"Sanchez","year":"2012","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"A randomised placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0042|cit42","first-page":"223","article-title":"Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia","volume":"13","author":"Kane","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008016.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/S0924-977X(09)70864-8","article-title":"Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia","volume":"19","author":"Mackle","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0044|cit44","unstructured":"A randomized, placebo-controlled, double-blind trial of asenapine in the prevention of relapse after long-term treatment of schizophrenia https:\/\/www.ClinicalTrials.gov\/ct\/show\/ 2005"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0045|cit45","unstructured":"The NHSC Asenapine (Saphris) for schizophrenia Report 2010"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0046|cit46","first-page":"148","article-title":"Effect of brexpiprazole on long-term functioning in adults with schizophrenia","volume":"51","author":"Baker","year":"2017","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1017\/S1092852918001086","article-title":"Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study","volume":"24","author":"Correll","year":"2019","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.1016\/S0924-977X(15)30727-6","article-title":"Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study","volume":"25","author":"Fleischhacker","year":"2015","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0049|cit49","first-page":"11","article-title":"Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0050|cit50","unstructured":"Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia https:\/\/ClinicalTrials.gov\/show\/NCT01668797 2012"},{"issue":"(Suppl.1)","key":"10.1002\/14651858.CD008016.pub3-BIB0051|cit51","first-page":"S244","article-title":"Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study","volume":"43","author":"Therrien","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1093\/schbul\/sbx024.111","article-title":"Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study","volume":"43","author":"Weiller","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1093\/schbul\/sbx023.113","article-title":"Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors","volume":"43","author":"Weiss","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0054|cit54","first-page":"S227","article-title":"Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study","volume":"40","author":"Weiss","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S556","DOI":"10.1016\/S0924-977X(16)31604-2","article-title":"Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia","volume":"26","author":"Weiss","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"(Suppl. 4)","key":"10.1002\/14651858.CD008016.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S935","DOI":"10.1016\/S0924-977X(17)31659-0","article-title":"Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial","volume":"27","author":"Correll","year":"2017","journal-title":"Europan Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0057|cit57","first-page":"18m12495","article-title":"Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial","volume":"80","author":"Correll","year":"2019","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0058|cit58","article-title":"Corrigendum to \"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial\" [Schizophr. Res. 176 (2016) 264-71]","volume":"InPress","author":"Durgam","year":"2017","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/S0924-977X(15)30705-7","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial","volume":"25","author":"Durgam","year":"2015","journal-title":"European Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD008016.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0061|cit61","first-page":"S380","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial","volume":"40","author":"Durgam","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.schres.2018.04.016","article-title":"Modified cariprazine relapse prevention clinical trial results","volume":"199","author":"Earley","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1093\/schbul\/sbx024.013","article-title":"Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial","volume":"43","author":"Kunovac","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0064|cit64","unstructured":"Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01412060 2011"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/schbul\/sbx023.013","article-title":"Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial","volume":"43","author":"Potkin","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0066|cit66","first-page":"452","article-title":"Comparison of chlorpromazine and reserpine in maintenance drug therapy","volume":"20","author":"Shawver","year":"1959","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0067|cit67","first-page":"522","article-title":"Prolonged withdrawal of chlorpromazine in chronic patients","volume":"23","author":"Freeman","year":"1962","journal-title":"Diseases of the Nervous System"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0068|cit68","first-page":"209","article-title":"Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs","volume":"9","author":"Crane","year":"1968","journal-title":"Agressologie"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0069|cit69","first-page":"19","article-title":"Incidence and significance of chlorpromazine-induced eye changes","volume":"29","author":"De Long","year":"1968","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0070|cit70","first-page":"983","article-title":"A 12-year follow-up study of chronic schizophrenics","volume":"33","author":"Gardos","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.115.523.679","article-title":"Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication","volume":"115","author":"Prien","year":"1968","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archpsyc.1968.01740040098013","article-title":"High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group","volume":"18","author":"Prien","year":"1968","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archpsyc.1970.01750050080011","article-title":"Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study","volume":"23","author":"Prien","year":"1970","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0074|cit74","first-page":"739","article-title":"Indications for high dose chlorpromazine therapy in chronic schizophrenia","volume":"31","author":"Prien","year":"1970","journal-title":"Diseases of the Nervous System"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0075|cit75","first-page":"4","article-title":"Discontinuation of chemotherapy for chronic schizophrenics","volume":"22","author":"Prien","year":"1971","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archpsyc.1977.01770140061008","article-title":"Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy","volume":"34","author":"Goldberg","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0077|cit77","unstructured":"Hogarty G Goldberg SC Drug and social therapy in schizophrenic outpatients Unknown Source 1994 18"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0078|cit78","first-page":"47","article-title":"Proceedings: drug and sociotherapy in the aftercare of schizophrenic patients","volume":"10","author":"Hogarty","year":"1974","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1974.01760170005001","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates","volume":"31","author":"Hogarty","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.1974.01760170011002","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients","volume":"31","author":"Hogarty","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archpsyc.1973.01750310038007","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates","volume":"28","author":"Hogarty","year":"1973","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00004714-198402000-00003","article-title":"Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate","volume":"4","author":"Hogarty","year":"1984","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archpsyc.1979.01780120013001","article-title":"Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride","volume":"36","author":"Hogarty","year":"1979","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/archpsyc.1977.01770150055005","article-title":"Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients","volume":"34","author":"Hogarty","year":"1977","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0085|cit85","first-page":"54","article-title":"NIHM-PRB collaborative outpatient schizophrenic study","volume":"10","author":"Hogarty","year":"1974","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0086|cit86","first-page":"909","article-title":"Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia","volume":"104","author":"Elie","year":"1975","journal-title":"Union Medicale du Canada"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.128.5.451","article-title":"A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients","volume":"128","author":"Andrews","year":"1976","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0088|cit88","first-page":"499","article-title":"The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics","volume":"14","author":"Rifkin","year":"1979","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0089|cit89","first-page":"40","article-title":"Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data","volume":"13","author":"Rifkin","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0090|cit90","first-page":"15","article-title":"Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data","volume":"34","author":"Rifkin","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0091|cit91","first-page":"24","article-title":"Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics","volume":"12","author":"Rifkin","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1977.01770130045004","article-title":"Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year","volume":"34","author":"Rifkin","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/ajp.136.2.217","article-title":"Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate","volume":"136","author":"Gelenberg","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0094|cit94","first-page":"483","article-title":"Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study","volume":"24","author":"Levine","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archpsyc.1982.04290020051010","article-title":"Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics","volume":"39","author":"Mandel","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0041-1723921","article-title":"The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine","volume":"9","author":"Schooler","year":"1976","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archpsyc.1980.01780140018002","article-title":"Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate","volume":"37","author":"Schooler","year":"1980","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0098|cit98","first-page":"44","article-title":"Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen","volume":"15","author":"Schooler","year":"1979","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0099|cit99","first-page":"29","article-title":"Dosage and side effect comparisons between oral and depot fluphenazine","volume":"13","author":"Schooler","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archpsyc.1982.04290010048009","article-title":"Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0101|cit101","first-page":"20","article-title":"Low-dose neuroleptics in outpatient schizophrenics","volume":"18","author":"Kane","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0033-3182(68)71862-4","article-title":"Maintenance treatment of schizophrenic outpatients with a depot phenothiazine","volume":"9","author":"Keskiner","year":"1968","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archpsyc.1968.01740040093012","article-title":"Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis","volume":"18","author":"Keskiner","year":"1968","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/026988119000400206","article-title":"Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients","volume":"4","author":"King","year":"1990","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0105|cit105","first-page":"66","article-title":"A controlled study of a very long-acting phenothiazine preparation","volume":"1","author":"Kinross-Wright","year":"1965","journal-title":"International Journal of Neuropsychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archpsyc.1960.01710060089013","article-title":"Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment","volume":"3","author":"Hankoff","year":"1960","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.1.5854.633","article-title":"Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry","volume":"1","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0108|cit108","first-page":"374","article-title":"Double-blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics","volume":"14","author":"Dotti","year":"1979","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0165-1781(79)90016-7","article-title":"Low dose fluphenazine decanoate in maintenance treatment of schizophrenia","volume":"1","author":"Kane","year":"1979","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/schbul\/9.4.528","article-title":"Low dose medication strategies in the maintenance treatment of schizophrenia","volume":"9","author":"Kane","year":"1983","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0111|cit111","first-page":"116","article-title":"The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics","volume":"17","author":"Goldberg","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-198105000-00005","article-title":"Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics","volume":"1","author":"Shenoy","year":"1981","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0113|cit113","first-page":"195","article-title":"Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients","volume":"43","author":"Odejide","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hup.470070405","article-title":"Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels","volume":"7","author":"Sampath","year":"1992","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.470050308","article-title":"Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment","volume":"5","author":"Soni","year":"1990","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0116|cit116","first-page":"99","article-title":"A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia","volume":"13","author":"Ota","year":"1973","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005053-199104000-00006","article-title":"Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial","volume":"179","author":"Ruskin","year":"1991","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0118|cit118","first-page":"650","article-title":"Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: double-blind comparison with placebo","volume":"31","author":"Zissis","year":"1982","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0119|cit119","first-page":"S7","article-title":"Minimal effective dose and relapse - double-blind trial: haloperidol decanoate vs. placebo","volume":"14","author":"Eklund","year":"1991","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0120|cit120","unstructured":"Eklund K Low dose of haloperidol decanoate is effective against relapses in schizophrenia patients. A double-blind placebo controlled study Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1990 287"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0121|cit121","unstructured":"A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use. http:\/\/ctri.nic.in\/Clinicaltrials\/login.php 2010"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0122|cit122","unstructured":"Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone http:\/\/ClinicalTrials.gov\/show\/NCT01291511 2011"},{"issue":"8","key":"10.1002\/14651858.CD008016.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40263-016-0345-4","article-title":"A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study","volume":"30","author":"Weiden","year":"2016","journal-title":"CNS drugs"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0124|cit124","unstructured":"PEARL Schizophrenia Maintenance http:\/\/ClinicalTrials.gov\/show\/NCT01435928 2011"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","author":"Tandon","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008016.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/S0924-977X(14)70896-X","article-title":"Lurasidone for maintenance of efficacy in patients with schizophrenia","volume":"24","author":"Tandon","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1016\/S0920-9964(14)71049-7","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"153","author":"Tandon","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0128|cit128","first-page":"S153","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"17","author":"Tandon","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0129|cit129","first-page":"277","article-title":"A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo","volume":"36","author":"Dellva","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00004714-199910000-00007","article-title":"Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo","volume":"19","author":"Tollefson","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Tollefson GD Dellva MA Mattler CA Kinon BJ Grundy SL A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80386-6"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008016.pub3-BIB0132|cit132","first-page":"S304","article-title":"Relapse prevention with olanzapine","volume":"10","author":"Hamilton","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0920-9964(00)90783-7","article-title":"Relapse prevention with olanzapine","volume":"41","author":"Beasley","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","article-title":"A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse","volume":"23","author":"Beasley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"S1","key":"10.1002\/14651858.CD008016.pub3-BIB0135|cit135","first-page":"S189","article-title":"Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?","volume":"30","author":"Beasley","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.jcp.0000195109.01898.5e","article-title":"Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?","volume":"26","author":"Beasley","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S0924-977X(03)92098-0","article-title":"The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia","volume":"13","author":"Beasley","year":"2003","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0138|cit138","unstructured":"Olanzapine relapse prevention versus placebo in the treatment of schizophrenia http:\/\/www.Clinicalstudyresults.org\/. 2005"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0139|cit139","unstructured":"Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia Sponsor: Johnson & Johnson Pharmaceutical Research & Development, LL.C 2010 NCT00111189"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0140|cit140","first-page":"438","article-title":"Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study","volume":"33","author":"Kramer","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008016.pub3-BIB0141|cit141","first-page":"S386","article-title":"Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets","volume":"16","author":"Kramer","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0142|cit142","first-page":"S274","article-title":"Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study","volume":"9","author":"Kramer","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD008016.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1017\/S1092852900000456","article-title":"One-year open-label safety and efficacy study of paliperidone extended-release","volume":"15","author":"Kramer","year":"2010","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1744-859X-12-22","article-title":"Long-acting injectable paliperidone palmitate versus oral paliperidone extended release","volume":"12","author":"Markowitz","year":"2013","journal-title":"Annals of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41537-018-0056-6","article-title":"Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse","volume":"4","author":"Wang","year":"2018","journal-title":"NPJ Schizophrenia"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pnpbp.2014.02.007","article-title":"Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia","volume":"53","author":"Rui","year":"2014","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0148|cit148","first-page":"69","article-title":"Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia","volume":"12","author":"Zhang","year":"2016","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0149|cit149","unstructured":"Alphs L Bossie C Kern-Sliwa J Haskins JT Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness Proceedings of the 162nd Annual Meeting of the American Psychiatric Association San Francisco, CA."},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0150|cit150","first-page":"17m11874","article-title":"Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study","volume":"79","author":"Emsley","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0269881110372817","article-title":"A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia","volume":"25","author":"Gopal","year":"2011","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0153|cit153","unstructured":"Gopal S Vijapurkar U Lim P Morozova M Eerdekens M Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association San Francisco, CA"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0154|cit154","unstructured":"Hough D Gopal S Vijapukar U Lim P Morozova M Eerdekens M Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0155|cit155","unstructured":"Hough D Gopal S Vijapurkar U Lim P Morozova M Eerdekens M Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry Washington, DC, USA Elsevier Science Inc 2008 S285 6"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD008016.pub3-BIB0156|cit156","first-page":"285S","article-title":"Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Hough","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/S0920-9964(12)70756-9","article-title":"Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia","volume":"136","author":"Hulihan","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"8","key":"10.1002\/14651858.CD008016.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1185\/03007995.2011.595000","article-title":"Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate","volume":"27","author":"Kozma","year":"2011","journal-title":"Current Medical Resarch and Opinion"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0160|cit160","first-page":"375","article-title":"Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia","volume":"8","author":"Sliwa","year":"2012","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1186\/1471-244X-14-52","article-title":"Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate","volume":"14","author":"Sliwa","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41537-018-0056-6","article-title":"Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse","volume":"4","author":"Wang","year":"2018","journal-title":"NPJ Schizophrenia"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0163|cit163","first-page":"S303","article-title":"Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder","volume":"41","author":"Bossie","year":"2015","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/NMD.0000000000000646","article-title":"Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder","volume":"205","author":"Bossie","year":"2017","journal-title":"Journal of Nervous and Mental Ddisease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1016\/S0924-977X(14)70856-9","article-title":"Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder","volume":"24","author":"Fu","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0166|cit166","first-page":"S312","article-title":"Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients","volume":"41","author":"Fu","year":"2015","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0167|cit167","first-page":"S365","article-title":"Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale","volume":"39","author":"Fu","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0168|cit168","first-page":"263S","article-title":"Paliperidone palmitate delays relapse in patients with schizoaffective disorder","volume":"1","author":"Fu","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0169|cit169","first-page":"S331","article-title":"Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder","volume":"39","author":"Fu","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/JCP.0000000000000535","article-title":"Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder","volume":"36","author":"Fu","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","article-title":"Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder","volume":"76","author":"Fu","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2017.04.004","article-title":"Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder","volume":"192","author":"Fu","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0173|cit173","first-page":"536","article-title":"Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder","volume":"21","author":"Joshi","year":"2015","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3111\/13696998.2015.1033424","article-title":"Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder","volume":"18","author":"Joshi","year":"2015","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0175|cit175","unstructured":"A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder http:\/\/ClinicalTrials.gov\/show\/NCT01193153 2010"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0176|cit176","first-page":"S193","article-title":"Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale","volume":"41","author":"Turkoz","year":"2015","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/eip.12685","article-title":"Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia","volume":"13","author":"Bell","year":"2019","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0178|cit178","first-page":"S302","article-title":"Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study","volume":"41","author":"Berwaerts","year":"2015","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0924-9338(15)30222-4","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"Berwaerts","year":"2015","journal-title":"European Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD008016.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0181|cit181","unstructured":"Chirila C Zheng Q Sawyerr G Nuamah I Healthcare resource use of paliperidone palmitate 3-month injection vs placebo 168th Annual Meeting of American Psychiatric Association; Toronto, Canada"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.biopsych.2017.02.322","article-title":"Potential biomarkers of impending schizophrenia relapse","volume":"(10 Suppl)","author":"Gopal","year":"2017","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41537-017-0025-5","article-title":"Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies","volume":"3","author":"Gopal","year":"2017","journal-title":"NPJ Schizophrenia"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/j.biopsych.2017.02.592","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis","volume":"81","author":"Mathews","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0185|cit185","unstructured":"A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01529515 2012"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41537-018-0056-6","article-title":"Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse","volume":"4","author":"Wang","year":"2018","journal-title":"NPJ Schizophrenia"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0187|cit187","first-page":"330","article-title":"Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. A controlled double-blind study","volume":"10","author":"Baro","year":"1970","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1176\/ajp.131.6.699","article-title":"Penfluridol: an efficacious long-acting oral antipsychotic compound","volume":"131","author":"Gallant","year":"1974","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-0447.1974.tb08210.x","article-title":"Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation","volume":"50","author":"Roelofs","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1974.tb08220.x","article-title":"A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia","volume":"50","author":"Vandecasteele","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/j.1552-4604.1975.tb02380.x","article-title":"Penfluridol: a long-acting oral neuroleptic. A controlled study","volume":"15","author":"Kurland","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0192|cit192","first-page":"12","article-title":"Penfluridol: once-a-week oral maintenance neuroleptic in the management of chronic schizophrenics","volume":"11","author":"Kurland","year":"1975","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0193|cit193","first-page":"333","article-title":"Penfluridol maintenance therapy in schizophrenia: a controlled study","volume":"29","author":"Channabasavanna","year":"1987","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1192\/bjp.109.460.422","article-title":"Withdrawal of perphenazine in chronic schizophrenia","volume":"109","author":"Whittaker","year":"1963","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0195|cit195","first-page":"304","article-title":"Pimozide in chronic schizophrenic patients","volume":"11","author":"Huber","year":"1971","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0196|cit196","first-page":"47","article-title":"Pimozide (OrapR, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up","volume":"76","author":"Denijs","year":"1973","journal-title":"Psychiatria, Neurologia, Neurochirurgia"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0197|cit197","unstructured":"A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo https:\/\/astrazenecagrouptrials.pharmacm.com\/ST\/Submission\/View?id=385 2003"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0198|cit198","unstructured":"A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo https:\/\/astrazenecagrouptrials.pharmacm.com\/ST\/Submission\/View?id=1418 2006"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0199|cit199","unstructured":"A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated) https:\/\/www.ClinicalTrials.gov\/ct\/show\/ 2005"},{"issue":"11","key":"10.1002\/14651858.CD008016.pub3-BIB0200|cit200","first-page":"34","article-title":"Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients","volume":"4","author":"Peuskens","year":"2007","journal-title":"Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e328337789b","article-title":"Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study","volume":"25","author":"Peuskens","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0202|cit202","doi-asserted-by":"crossref","unstructured":"Peuskens J Trivedi JK Brecher M Svensson O Miller F Meulien D Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008","DOI":"10.1016\/j.schres.2007.12.027"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2007.12.027","article-title":"Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate","volume":"98","author":"Peuskens","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0204|cit204","doi-asserted-by":"crossref","unstructured":"Peuskens J Trivedi JK Malyarov S Brecher M Svensson O Miller F A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA 2007","DOI":"10.1016\/j.eurpsy.2007.01.424"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0205|cit205","first-page":"453","article-title":"A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia","volume":"33","author":"Peuskens","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0206|cit206","unstructured":"A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00658645?term=NCT00658645&rank=1"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0207|cit207","unstructured":"A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00704509?term=NCT00704509&rank=1"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/schbul\/sby015.240","article-title":"The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis","volume":"44","author":"Chen","year":"2018","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0209|cit209","first-page":"A5","article-title":"Assessing the efficacy of relapse prevention in single episode psychosis patients with stable maintenance treatment for at least 1 year: a double-blind randomized placebo-controlled","volume":"2","author":"Chen","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2007.12.020","article-title":"A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy","volume":"98","author":"Chen","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0211|cit211","first-page":"13","article-title":"A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment","volume":"4","author":"Chen","year":"2010","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"c4024","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.eurpsy.2008.01.760","article-title":"A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy","volume":"23","author":"Chen","year":"2008","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.schres.2013.08.010","article-title":"Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis","volume":"150","author":"Hui C","year":"2013","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0215|cit215","first-page":"A124","article-title":"Can we predict relapse in single episode psychosis patients with stable maintenance treatment for at least one year?","volume":"2","author":"Hui","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.12.023","article-title":"Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients","volume":"98","author":"Hui","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0217|cit217","first-page":"46","article-title":"The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis","volume":"12","author":"Hui","year":"2018","journal-title":"Early Intervention in Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"Hui","journal-title":"Lancet Psychiatry"},{"issue":"13","key":"10.1002\/14651858.CD008016.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1017\/S0033291718003070","article-title":"Predicting first-episode psychosis patients who will never relapse over 10 years","volume":"49","author":"Hui","year":"2019","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamapsychiatry.2018.3120","article-title":"Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: a 10-year follow-up","volume":"76","author":"Hui","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1017\/S0033291716000751","article-title":"Visual working memory deterioration preceding relapse in psychosis","volume":"46","author":"Hui","year":"2016","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.eurpsy.2008.01.804","article-title":"A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients","volume":"23","author":"Hui","year":"2008","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0223|cit223","unstructured":"Duration of maintenance anti-psychotic therapy after first -episode schizophrenia: a double-blind randomized placebo-control relapse prevention study https:\/\/www.ClinicalTrials.gov\/ct\/show\/ 2006"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1176\/ajp.126.3.305","article-title":"High dose trifluoperazine therapy in chronic schizophrenia","volume":"126","author":"Prien","year":"1969","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0225|cit225","first-page":"4","article-title":"Discontinuation of chemotherapy for chronic schizophrenics","volume":"22","author":"Prien","year":"1971","journal-title":"Hospital and Community Psychiatry"},{"issue":"554","key":"10.1002\/14651858.CD008016.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1192\/bjp.120.554.41","article-title":"Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy","volume":"120","author":"Hershon","year":"1972","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S0033291700048480","article-title":"Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community","volume":"3","author":"Stevens","year":"1973","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1176\/ajp.116.10.931","article-title":"Discontinuation of treatment with ataractic drugs. A preliminary report","volume":"116","author":"Gross","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0229|cit229","first-page":"151","article-title":"A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients","volume":"22","author":"Schiele","year":"1961","journal-title":"Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/00005053-196202000-00005","article-title":"Intermittent chemotherapy for chronic psychiatric inpatients","volume":"134","author":"Olson","year":"1962","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005053-196009000-00007","article-title":"Sudden removal of tranquilizing drugs from chronic psychiatric patients","volume":"131","author":"Olson","year":"1960","journal-title":"Journal of Mental and Nervous Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0232|cit232","first-page":"11","article-title":"Maintenance phenothiazines in aftercare of schizophrenic patients","volume":"2","author":"Troshinsky","year":"1962","journal-title":"Pennsylvania Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0021-9681(64)90075-X","article-title":"Discontinuation or reduction of chemotherapy in chronic schizophrenics","volume":"17","author":"Caffey","year":"1964","journal-title":"Journal of Chronic Diseases"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.120.6.578","article-title":"Phenothiazine excretion in chronic schizophrenics","volume":"120","author":"Caffey","year":"1963","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/070674376400900404","article-title":"Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients","volume":"9","author":"Marjerrison","year":"1964","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0236|cit236","first-page":"321","article-title":"Withdrawal of ataractic medication in schizophrenic patients","volume":"27","author":"Garfield","year":"1966","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/070674376601100507","article-title":"Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients","volume":"11","author":"Melnyk","year":"1966","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1176\/ajp.124.11.1585","article-title":"A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia","volume":"124","author":"Morton","year":"1968","journal-title":"American Journal of Psychiatry"},{"issue":"854","key":"10.1002\/14651858.CD008016.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.1.5854.633","article-title":"Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry","volume":"1","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"issue":"5868","key":"10.1002\/14651858.CD008016.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/bmj.2.5868.715-d","article-title":"Outpatient maintenance of chronic schizophrenics with long-acting","volume":"2","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1192\/bjp.123.6.659","article-title":"Life events and maintenance therapy in schizophrenic relapse","volume":"123","author":"Leff","year":"1973","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bmj.3.5775.599","article-title":"Trial of maintenance therapy in schizophrenia","volume":"3","author":"Leff","year":"1971","journal-title":"British Medical Journal"},{"issue":"5885","key":"10.1002\/14651858.CD008016.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmj.4.5885.156","article-title":"Influence of selection of patients on results of clinical trials","volume":"4","author":"Leff","year":"1973","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0244|cit244","first-page":"792","article-title":"The social value of fluphenazine decanoate","volume":"76","author":"Stevens","year":"1976","journal-title":"Acta Psychiatrica Belgica"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S0033291700048480","article-title":"Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community","volume":"3","author":"Stevens","year":"1973","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0246|cit246","first-page":"696","article-title":"A double-blind comparison of once-a-day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients","volume":"16","author":"Gross","year":"1974","journal-title":"Current Therapeutic Research"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0247|cit247","first-page":"137","article-title":"Pimozide in chronic schizophrenic outpatients","volume":"36","author":"Clark","year":"1975","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0248|cit248","first-page":"59","article-title":"Pimozide vs thioridazine vs placebo","volume":"9","year":"1973","journal-title":"Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00005053-196110000-00005","article-title":"Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics","volume":"133","author":"Blackburn","year":"1981","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1192\/bjp.138.6.490","article-title":"Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?","volume":"138","author":"Cheung","year":"1981","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0252|cit252","first-page":"369","article-title":"Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics","volume":"44","author":"Wistedt","year":"1983","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0447.1983.tb09718.x","article-title":"Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology","volume":"67","author":"Wistedt","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00427950","article-title":"A depot neuroleptic withdrawal study neurological effects","volume":"80","author":"Wistedt","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1981.tb00761.x","article-title":"A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients","volume":"64","author":"Wistedt","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archpsyc.1982.04290060085019","article-title":"Neuroleptics and depression","volume":"39","author":"Wistedt","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00432759","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenia","volume":"77","author":"Nishikawa","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archpsyc.1983.01790220020003","article-title":"Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures","volume":"41","author":"Gardos","year":"1984","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00427763","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose response study of haloperidol and propericiazine","volume":"82","author":"Nishikawa","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.148.2.120","article-title":"A randomised controlled trial of prophylactic neuroleptic treatment","volume":"148","author":"Crow","year":"1986","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/schbul\/12.3.394","article-title":"Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics","volume":"12","author":"Spohn","year":"1986","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0447.1989.tb03032.x","article-title":"The Scottish first episode schizophrenia study. VII two-year follow-up","volume":"80","author":"McCreadie","year":"1989","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1192\/bjp.150.3.334","article-title":"The Scottish First Episode Schizophrenia Study II. Treatment","volume":"150","author":"Scottish Schizophrenia Research Group","year":"1987","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1192\/bjp.152.4.470","article-title":"The Scottish First Episode Schizophrenia Study V. One-year follow-up","volume":"152","author":"Scottish Schizophrenia Research Group","year":"1988","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1192\/bjp.150.3.338","article-title":"The Scottish First Episode Schizophrenia Study. III. Cognitive performance","volume":"150","author":"Scottish Schizophrenia Research Group","year":"1987","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1192\/bjp.161.4.496","article-title":"The Scottish first episode schizophrenia study. VIII. Five-year follow-up","volume":"161","author":"Scottish Schizophrenia Research Group","year":"1992","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/S0007125000292416","article-title":"Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?","volume":"163","author":"Gaebel","year":"1993","journal-title":"British Journal of Psychiatry Supplementum"},{"issue":"1-2","key":"10.1002\/14651858.CD008016.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-9964(01)00182-7","article-title":"First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies","volume":"53","author":"Gaebel","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0269|cit269","unstructured":"Gaebel W Moeller HJ Treatment strategies in first episode schizophrenia Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0022-3956(93)90059-B","article-title":"Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study","volume":"27","author":"Pietzcker","year":"1993","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2007-1017177","article-title":"A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report","volume":"19","author":"Pietzcker","year":"1986","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/13651501.2010.534801","article-title":"Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial","volume":"15","author":"Boonstra","year":"2011","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0273|cit273","unstructured":"Boonstra G Schizophrenia termination of pharmacotherapy-STOP-trial Current Controlled Trials 2005"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0274|cit274","unstructured":"Arato M O'Connor R Bradbury JE Meltzer H Long-term ziprasidone in schizophrenia Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada 1998"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0275|cit275","unstructured":"Arato M O'Connor R Bradbury JE Meltzer H The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK Amsterdam, Netherlands Cambridge University Press 1998"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0276|cit276","unstructured":"Arato M O'Connor R Bradbury JE Meltzer H Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark 1998"},{"issue":"1-3","key":"10.1002\/14651858.CD008016.pub3-BIB0277|cit277","first-page":"270","article-title":"Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia","volume":"36","author":"Arato","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0278|cit278","unstructured":"Arato M O'Connor R Meltzer H Bradbury J Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD008016.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00044011-200626080-00003","article-title":"Cost-effectiveness analysis of schizophrenia relapse prevention","volume":"26","author":"Bernardo","year":"2006","journal-title":"Clinical Drug Investigation. New Zealand"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0281|cit281","first-page":"259","article-title":"Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS)","volume":"35","author":"Bernardo","year":"2007","journal-title":"Acta Espanolas de Psiquiatria"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0282|cit282","first-page":"S. 239","article-title":"Long-term efficacy of ziprasidone in schizophrenia","volume":"(1-2)","author":"Meltzer","year":"2001","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0283|cit283","unstructured":"Meltzer HY O\u00b4Connor R Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia Conference Poster 1997"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0284|cit284","unstructured":"Meltzer HY O'Connor R Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0920-9964(02)00309-2","article-title":"Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]","volume":"60","author":"O'Connor","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0286|cit286","unstructured":"Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia Study report"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0287|cit287","unstructured":"Schooler N A basis for optimism: the implications of long term treatment Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark 1998"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"41s","DOI":"10.1016\/S0006-3223(97)87049-7","article-title":"Zotepine in the prevention of relapse","volume":"42","author":"Cooper","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0289|cit289","unstructured":"Cooper SJ Butler A Tweed J Raniwalla J Welch C Zotepine in the prevention of relapse Proceedings of the 6th World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France 1997"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s002130000452","article-title":"Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia","volume":"150","author":"Cooper","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0291|cit291","doi-asserted-by":"crossref","unstructured":"Cooper SJ Butler A Tweed JA Welch CP Wighton AJ Appleby P Zotepine is effective in preventing recurrence in patients with chronic schizophrenia Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80394-5"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0920-9964(00)90814-4","article-title":"Zotepine is effective in preventing recurrence in patients with chronic schizophrenia","volume":"41","author":"Cooper","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0293|cit293","unstructured":"Allen DN Gilbertson MW Barry E Kammen DP Gurklis JA Haloperidol improves memory in schizophrenia Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004850-200503000-00003","article-title":"Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study","volume":"20","author":"Bai","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","article-title":"Risperidone for severe tardive dyskinesia: a 12 week randomised, double-blind, placebo-controlled study","volume":"64","author":"Bai","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0296|cit296","first-page":"40","article-title":"PREVENT: a randomized controlled trial comparing cognitive behavioural therapy, clinical management and aripiprazole and clinical management and placebo for the prevention of first episode psychosis","volume":"10","author":"Bechdolf","year":"2016","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.psychres.2017.08.068","article-title":"Symptomatic remission in schizophrenia: results from a risperidone maintenance treatment study","volume":"258","author":"Bo","year":"2017","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.12.371","article-title":"Efficacy of bifeprunox in patients in the post-acute, maintenance phase of schizophrenia: findings from a 6-month study","volume":"98","author":"Bourin","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0299|cit299","first-page":"118","article-title":"Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia","volume":"17","author":"Branchey","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1176\/ajp.138.5.608","article-title":"Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients","volume":"138","author":"Branchey","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1176\/ajp.144.12.1549","article-title":"Neuroleptic responsivity of negative and positive symptoms in schizophrenia","volume":"144","author":"Breier","year":"1987","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40120-017-0085-5","article-title":"A phase IC study evaluating the safety, tolerability, pharmacokinetics and cognitive outcomes of BI409306 in patients with mild to moderate schizophrenia","volume":"7","author":"Brown","year":"2018","journal-title":"Neurology and Therapy"},{"issue":"9","key":"10.1002\/14651858.CD008016.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.biopsych.2018.02.542","article-title":"Effects of BI409306 on positive and negative syndrome scale in schizophrenia: a randomized double-blind placebo-controlled phase II trial","volume":"83","author":"Sand","year":"2018","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.psychres.2018.06.055","article-title":"Impact of comprehensive treatment for first episode psychosis and substance use outcomes: a randomized controlled trial","volume":"268","author":"Cather","year":"2018","journal-title":"Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/schbul\/sbx096","article-title":"Prospective relationships between motivation and functioning in recovery after a first episode of schizophrenia","volume":"44","author":"Fulford","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2018.08.015","article-title":"Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study","volume":"204","author":"Mueser","year":"2019","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0307|cit307","first-page":"149","article-title":"Elements of recovery in first episode psychosis: developing measurable criteria","volume":"10","author":"Schooler","year":"2016","journal-title":"Early Interventions in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.psychres.2019.01.068","article-title":"Rates and predictors of one year antipsychotic treatment discontinuation in first episode schizophrenia: results from ab open-label randomized \"real-world\" clinical trial","volume":"273","author":"Cheng","year":"2019","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1093\/schbul\/sbz021.209","article-title":"Gray matter changes in medicated and unmedicated first episode psychosis: a randomized placebo-controlled trial","volume":"45","author":"Chopra","year":"2019","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0447.1981.tb00794.x","article-title":"Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system","volume":"64","author":"Chouinard","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0311|cit311","unstructured":"Andris J Clinical trials van risperidone Unknown Source 1997 14"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00004714-199708000-00010","article-title":"Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol","volume":"17","author":"Chouinard","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0006-3223(92)90579-O","article-title":"The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients","volume":"31","author":"Chouinard","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0315|cit315","doi-asserted-by":"crossref","unstructured":"Chouinard G Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study Journal of Clinical Psychopharmacology 1995 15 Suppl 1 S36 44","DOI":"10.1097\/00004714-199502001-00007"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004714-199508000-00002","article-title":"Effect of risperidone on hostility in schizophrenia","volume":"15","author":"Czobor","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD008016.pub3-BIB0317|cit317","first-page":"538","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD008016.pub3-BIB0318|cit318","first-page":"18","article-title":"Efficacy of risperidone on positive features of schizophrenia","volume":"55","author":"McEvoy","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","article-title":"A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re- evaluation of the North American risperidone study","volume":"245","author":"Moller","year":"1995","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00004714-199506000-00016","article-title":"Critique of the Canadian multicenter placebo-controlled study of risperidone and haloperidol","volume":"15","author":"Musser","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0321|cit321","unstructured":"Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia https:\/\/www.ClinicalTrials.gov\/ct\/show\/ 2005"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00004714-199706000-00010","article-title":"Extrapyramidal symptoms in patients treated with risperidone","volume":"17","author":"Simpson","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archpsyc.1974.01760150069010","article-title":"Group therapy and maintenance treatment of schizophrenics","volume":"31","author":"Claghorn","year":"1974","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00006842-196711000-00008","article-title":"Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships","volume":"29","author":"Clark","year":"1967","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1192\/bjp.113.505.1425","article-title":"A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics","volume":"113","author":"Collins","year":"1967","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0006-3223(95)00378-T","article-title":"Language comprehension in schizophrenia: trait or state indicator?","volume":"38","author":"Condray","year":"1995","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0327|cit327","first-page":"469","article-title":"Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine\/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.146.5.464","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine- placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1192\/bjp.146.5.474","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008016.pub3-BIB0330|cit330","first-page":"890","article-title":"Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients","volume":"20","author":"Degkwitz","year":"1970","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005053-196009000-00006","article-title":"Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage","volume":"131","author":"Diamond","year":"1960","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0447.1993.tb03477.x","article-title":"Efficacy of maintenance use of anticholinergic agents","volume":"88","author":"Double","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0333|cit333","first-page":"32","article-title":"Effects of ethopropazine and trihexyphenidyl on several parameters of the neuroleptic syndrome","volume":"61","author":"Elie","year":"1972","journal-title":"Encephale"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/j.euroneuro.2018.11.633","article-title":"Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: post hoc analysis versus aripiprazole","volume":"29","author":"Barabassy","year":"2019","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/S0924-977X(16)31597-8","article-title":"Efficacy of cariprazine in negative, cognitive, social function symptoms in schizophrenia: post hoc analysis of a randomized controlled trial","volume":"26","author":"Cutler","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0336|cit336","unstructured":"Durgam S Earley W Lu K N\u00e9meth G Laszlovszky I Szatmari B Patel M Nasrallah H Cariprazine for negative symptoms of schizophrenia: a pooled post-hoc analysis of 2 randomized double-blind placebo and active controlled trials 29th European College of Neuropsychopharmacology Congress Vienna, Austria"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analysis from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1967.01730190100013","article-title":"Phenothiazines in prevention of psychiatric hospitalisation","volume":"16","author":"Engelhardt","year":"1967","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"British Journal of Psychiatriy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0340|cit340","first-page":"70","article-title":"Antipsychotic medication in first episode psychosis: an RCT to assess the risk benefit ratio","volume":"12","author":"Francey","year":"2018","journal-title":"Early Intervention in Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0341|cit341","first-page":"9","article-title":"A randomized placebo-controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first episode psychosis with low risk of self harm of aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis","volume":"10","author":"Francey","year":"2016","journal-title":"Early Interventions in Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/eip.12716","article-title":"Staged treatment and acceptability guidelines in early psychosis study (STAGES): a randomized placebo-controlled trial of intensive psychosocial treatment plusof minus antipsychotic medication for first episode with low risk of self harm or aggression: study protocol and baseline characteristics of patients","volume":"13","author":"O'Donoghue","year":"2019","journal-title":"Early Interventions in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0447.1982.tb00819.x","article-title":"Clonidine treatment of schizophrenia: double blind comparison to placebo and neuroleptic drugs","volume":"65","author":"Freedman","year":"1982","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/ajp.121.5.491","article-title":"Withdrawal symptoms after abrupt cessation of antipsychotic compounds: clinical confirmation in chronic schizophrenics","volume":"121","author":"Gallant","year":"1964","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00004714-198802000-00010","article-title":"Persistence of fluphenazine in plasma after decanoate withdrawal","volume":"8","author":"Gitlin","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","article-title":"Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia","volume":"158","author":"Gitlin","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0347|cit347","first-page":"61","article-title":"Episode ii: prevention of relapse following early psychosis","volume":"70","author":"Gleeson","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00005053-196708000-00008","article-title":"Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time","volume":"145","author":"Goldberg","year":"1967","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005053-195808000-00009","article-title":"Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics","volume":"127","author":"Labrosse","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.115.5.443","article-title":"Termination of chlorpromazine with schizophrenic patients","volume":"115","author":"Good","year":"1958","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005053-195808000-00009","article-title":"Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics","volume":"127","author":"Mefferd","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/ajp.123.2.221","article-title":"Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients","volume":"123","author":"Greenberg","year":"1966","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005053-195809000-00002","article-title":"Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic","volume":"127","author":"Hine","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0920-9964(89)90002-9","article-title":"Dysphoric and depressive symptoms in chronic schizophrenia.","volume":"2","author":"Hirsch","year":"1989","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0355|cit355","first-page":"94","volume-title":"Schizophrenie Als Systemische Stoerung. Die Bedeutung Intermediaerer Prozesse Fuer Theorie Und Therapie","author":"Hirsch","year":"1989"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD008016.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S0007125000295986","article-title":"The dysphoric syndrome in schizophrenia and its implications for relapse","volume":"155","author":"Hirsch","year":"1989","journal-title":"British Journal of Psychiatry. Supplements"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.168.1.49","article-title":"A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse","volume":"168","author":"Hirsch","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0920-9964(93)90613-N","article-title":"The effect of life events and medication in the aetiology of schizophrenic relapse","volume":"9","author":"Hirsch","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1192\/bjp.113.505.1419","article-title":"A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics","volume":"113","author":"Hunt","year":"1967","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0360|cit360","first-page":"33","article-title":"Penfluridol in the maintenance therapy of schizophrenia","volume":"21","author":"Ionescu","year":"1983","journal-title":"Neurologie et Psychiatrie"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0361|cit361","first-page":"608","article-title":"The effects of withdrawal of trifluoperazine on patients maintained on the combination of tranylcypromine and trifluoperazine: a double-blind study","volume":"85","author":"Janecek","year":"1963","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(88)90682-4","article-title":"The Northwick Park \"functional\" psychosis study: diagnosis and treatment response","volume":"2","author":"Johnstone","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/026988119100500433","article-title":"The Northwick Park 'functional' psychosis study. Phase 2 - maintenance treatment","volume":"5","author":"Johnstone","year":"1991","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0364|cit364","unstructured":"Johnstone EC Owens DGC Does early treatment have an effect on outcome? Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0365|cit365","first-page":"17m11753","article-title":"Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial","volume":"79","author":"Keefe","year":"2018","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0447.1971.tb02203.x","article-title":"A double-blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy","volume":"47","author":"Kellam","year":"1971","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.schres.2004.05.006","article-title":"Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia","volume":"72","author":"Lauriello","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0368|cit368","unstructured":"Lecrubier Y Amisulpride in deficit schizophrenia Proceedings of the 6th World Congress Biological Psychiatry, 1997 Jun 22-27; Nice, France 1997"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/schbul\/sby018.1014","article-title":"A proposed alternative between discontinuation and maintenance of antipsychotics: a guided dose reduction trial for patients with remitted psychosis","volume":"44","author":"Liu","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia","volume":"170","author":"Loo","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0371|cit371","first-page":"45","article-title":"A double blind placebo controlled trial of pimozide (R6238) on 49 hospitalized chronic schizophrenics","volume":"17","author":"Mahal","year":"1975","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0372|cit372","unstructured":"Andris J Clinical trials van risperidone Unknown Source 1997 14"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004714-199508000-00002","article-title":"Effect of risperidone on hostility in schizophrenia","volume":"15","author":"Czobor","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00004714-199310000-00006","article-title":"Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients","volume":"13","author":"Czobor","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0375|cit375","unstructured":"Lindenmayer JP =The RSG Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco, California, USA 1993"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0376|cit376","unstructured":"Marder S Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia Clinical Research Report (RIS-INT-3) 1991"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0377|cit377","unstructured":"Marder SR Chouinard G Davis JM The clinical actions of risperidone Proceedings of the 10th Congress of the European College of Neuropsychopahrmacology; 1997 Sep 13-17, Vienna, Austria 1997"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0378|cit378","unstructured":"Marder SR Chouinard G Davis JM The clinical actions of risperidone Proceedings of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9-13; San Juan, Puerto Rico 1996"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0379|cit379","unstructured":"Marder SR Chouinard G Davis JM The clinical actions of risperidone Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France 1997"},{"issue":"12","key":"10.1002\/14651858.CD008016.pub3-BIB0380|cit380","first-page":"538","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub3-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD008016.pub3-BIB0382|cit382","first-page":"18","article-title":"Efficacy of risperidone on positive features of schizophrenia","volume":"55","author":"McEvoy","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","article-title":"A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re- evaluation of the North American risperidone study","volume":"245","author":"Moller","year":"1995","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0384|cit384","unstructured":"Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia https:\/\/www.ClinicalTrials.gov\/ct\/show\/ 2005"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00004714-199706000-00010","article-title":"Extrapyramidal symptoms in patients treated with risperidone","volume":"17","author":"Simpson","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1192\/bjp.138.3.271a","article-title":"Phenothiazine withdrawal in schizophrenics in a hostel","volume":"138","author":"Mathur","year":"1981","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1016\/j.euroneuro.2018.11.641","article-title":"Short term efficacy of brexpiprazole in patients with schizophrenia with clinically relevant levels of negative symptoms","volume":"29","author":"Meehan","year":"2019","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005053-195808000-00009","article-title":"Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics","volume":"127","author":"Mefferd","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.NMD.0000061148.84257.F9","article-title":"Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project","volume":"191","author":"Bola","year":"2003","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/schbul\/5.2.322","article-title":"A non neuroleptic treatment for schizophrenia: analysis of the two year postdischarge risk of relapse","volume":"5","author":"Matthews","year":"1979","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1939-0025.1975.tb02556.x","article-title":"Soteria: evaluation of a home-based treatment for schizophrenia","volume":"45","author":"Mosher","year":"1975","journal-title":"American Journal of Orthopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0392|cit392","first-page":"715","article-title":"Community residential treatment for schizophrenia: two year follow up","volume":"29","author":"Mosher","year":"1978","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0393|cit393","first-page":"1","article-title":"To prevent relapse of schizophrenic psychoses","volume":"14","author":"M\u00fcller","year":"1982","journal-title":"Ferdinand Enke Verlag Stuttgart"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0394|cit394","unstructured":"Research into antipsychotic discontinuation and reduction (RADAR): a randomized controlled trial https:\/\/clinicaltrials.gov\/"},{"issue":"7","key":"10.1002\/14651858.CD008016.pub3-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-3223(89)90265-5","article-title":"Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride","volume":"25","author":"Nishikawa","year":"1989","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0396|cit396","unstructured":"Nishikawa T Personal Communication Personal Communication 2009"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0397|cit397","unstructured":"Oosthuizen PP Treatment of first episode schizophrenia with low-dose haloperidol: a study in the Western Cape province of South Africa Dissertation presented for the Degree of Doctor of Philosophy at the University of Stellenbosch"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1939-0025.1972.tb02504.x","article-title":"The prevention of hospitalization in schizophrenia: five years after an experimental program","volume":"42","author":"Davis","year":"1972","journal-title":"American Journal of Orthopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0399|cit399","volume-title":"Schizophrenic in theCcommunity: an Experimental Study in the Prevention of Hospitalisation","author":"Pasamanick","year":"1967"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.1964.03060160005001","article-title":"Home vs hospital care for schizophrenics","volume":"187","author":"Pasamanick","year":"1964","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/archpsyc.1972.01750250092013","article-title":"Maintenance psychotropic drugs in the presence of active treatment programs. A \"triple-blind\" withdrawal study with long-term mental patients","volume":"27","author":"Paul","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1192\/bjp.139.2.112","article-title":"Propranolol in schizophrenia II. Clinical and biochemical aspects of combining propranolol with chlorpromazine","volume":"138","author":"Peet","year":"1981","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.1986.01800070059008","article-title":"Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment","volume":"43","author":"Pickar","year":"1986","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1176\/appi.ajp.160.6.1133","article-title":"Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia","volume":"160","author":"Pickar","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"28P","DOI":"10.1042\/cs044028Pa","article-title":"Measurement of drug action in schizophrenia","volume":"44","author":"Pigache","year":"1973","journal-title":"Clinical Science"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0406|cit406","first-page":"160","article-title":"Selective attention as an index of the anti-psychotic action of chlorpromazine in schizophrenia","volume":"20","author":"Pigache","year":"1973","journal-title":"British Psychological Society Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0920-9964(93)90076-U","article-title":"Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study","volume":"10","author":"Pigache","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0920-9964(93)90075-T","article-title":"The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia with placebo substitution for chlorpromazine","volume":"10","author":"Pigache","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00127-003-0601-z","article-title":"Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia","volume":"38","author":"Ran","year":"2003","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0410|cit410","first-page":"98","article-title":"A control study of psychoeducational family intervention for relatives of schizophrenics in a Chinese rural community","volume":"34","author":"Ran","year":"2001","journal-title":"Chinese Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0411|cit411","unstructured":"Ran MS Community mental health in China - A randomized controlled trial of psychoeducational family intervention for carers of persons with schizophrenia in a rural area in Chengdu http:\/\/hdl.handle.net\/10722\/35402"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0412|cit412","first-page":"216","article-title":"Withdrawal of antipsychotic drugs from chronic psychiatric patients","volume":"34","author":"Rassidakis","year":"1970","journal-title":"Bulletin of the Menninger Clinic"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0413|cit413","first-page":"33","article-title":"A controlled study of fluphenazine enanthate in chronic schizophrenic patients","volume":"25","author":"Ravaris","year":"1965","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1176\/ajp.124.2.248","article-title":"Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication","volume":"124","author":"Ravaris","year":"1967","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0415|cit415","first-page":"247","article-title":"A clinical study with pimozide in chronic schizophrenics","volume":"12","author":"Ruiz Ruiz","year":"1975","journal-title":"Revista de Psiquiatria Y Psicologia Medica de Europa Y America Latinas"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0416|cit416","unstructured":"Clinical trial to evaluate the efficacy of treatment vs discontinuation in a first episode of non-affective psychosis (NONSTOP) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01765829?term=NCT01765829&rank=1 2013"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0417|cit417","first-page":"642","article-title":"A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate","volume":"23","author":"Schlossberg","year":"1978","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.4.5778.22","article-title":"Thiopropazate hydrochloride in persistent dyskinesia","volume":"4","author":"Singer","year":"1971","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0419|cit419","first-page":"319","article-title":"Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis","volume":"51","author":"Singh","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.jcp.0000245562.99036.92","article-title":"Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use","volume":"26","author":"Smelson","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.470050308","article-title":"Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment","volume":"5","author":"Soni","year":"1990","journal-title":"Human Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1093\/schbul\/sby016.330","article-title":"Tailor tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia spectrum disorders in remission of psychotic symptoms","volume":"44","author":"Dolmer","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0423|cit423","unstructured":"TAILOR - a randomized clinical trial: Tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophreniform psychosis in remission of psychotic symptoms https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2016-000565-23 2017"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0424|cit424","first-page":"141","article-title":"Discontinuation versus maintenance therapy with antipsychotic medication in schizophrenia. TAILOR: a randomized controlled trial","volume":"12","author":"Stuerup","year":"2018","journal-title":"Early Interventions in Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s13063-017-2172-4","article-title":"TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial","volume":"18","author":"Stuerup","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0426|cit426","unstructured":"Randomized, placebo-controlled, double-blind, parallel-group, confirmatory study of SM-13496 (lurasidone HCl) in patients with schizophrenia: a phase III study Summary of study results. Sumitomo Dainippon Pharma Reports 2008"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF00180839","article-title":"A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients","volume":"88","author":"Vaddadi","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1176\/ajp.139.8.991","article-title":"D-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia","volume":"139","author":"Van Kammen","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0429|cit429","first-page":"655","article-title":"Amphetamine-induced catecholamine activation in schizophrenia and depression: behavioral and physiological effects","volume":"16","author":"Van Kammen","year":"1977","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archpsyc.1980.01780160057006","article-title":"Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients","volume":"37","author":"Van Kammen","year":"1980","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/0024-3205(78)90130-3","article-title":"D amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment","volume":"23","author":"Van Kammen","year":"1978","journal-title":"Life Sciences"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/schbul\/sby018.831","article-title":"Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study","volume":"44","author":"Vanover","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1176\/ajp.130.7.801","article-title":"Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects","volume":"130","author":"Van Praak","year":"1973","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008016.pub3-BIB0434|cit434","first-page":"207","article-title":"Less is more? An Australian RCT comparing dose reduction of anti-psychotic medication to maintenance treatment","volume":"12","author":"Weller","year":"2018","journal-title":"Early Interventions in Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub3-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/eip.12769","article-title":"Can antipsychotic dose reduction lead to better functional recovery in first episode psychosis? A randomized controlled trial of antipsychotic dose reduction: the REDUCE trial: study protocol","volume":"13","author":"Weller","year":"2019","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s004060170056","article-title":"Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia","volume":"251","author":"Wiedemann","year":"2001","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/070674376400900411","article-title":"Value of continuous drug administration for chronic long-term mental hospital patients","volume":"60","author":"Wright","year":"1964","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eurpsy.2011.02.003","article-title":"The effect of guided discontinuation of antipsychotics on neurocognition in first onset psychosis","volume":"27","author":"Faber","year":"2012","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0920-9964(06)70152-9","article-title":"Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome","volume":"86","author":"Wunderink","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.1956.02960380027008","article-title":"Use of chlorpromazine and reserpine in the treatment of emotional disorders","volume":"160","author":"Zeller","year":"1956","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41537-018-0054-8","article-title":"The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: a causal mediation analysis approach","volume":"4","author":"Zou","year":"2018","journal-title":"NPJ Schizophrenia"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0442|cit442","first-page":"83","article-title":"Penfluridol (R 16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients","volume":"76","year":"1973","journal-title":"Psychiatria, Neurologia, Neurochirurgia"},{"issue":"Suppl 1, Abstra","key":"10.1002\/14651858.CD008016.pub3-BIB0443|cit443","first-page":"96","article-title":"Differences between schizophrenia patients who switch vs discontinue antipsychotic therapy","volume":"37","author":"Ascher-Svanum","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0444|cit444","unstructured":"Decot H Zhang F Weinberger DR Apud J Effect of placebo and reintroduction of antipsychotics in patients with schizophrenia based on COMT Val108\/158Met polymorphism International Congress on Schizophrenia Research 84, downloaded from: schizophreniabulletin.oxfordjournals.org, 2011"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0445|cit445","first-page":"S223","article-title":"Neuroleptic-induced striatal blood flow changes and neurocognitive functioning in schizophrenia","volume":"41","author":"Eisenberg","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0446|cit446","unstructured":"A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patients with stable schizophrenia www.clinicaltrialsregister.eu"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0447|cit447","first-page":"182","article-title":"Double blind study of the contact between antipsychotic and the negative symptoms of the deteriorated schizophrenia","volume":"3","author":"Zhang","year":"2006","journal-title":"Medical Journal of Chinese People Health"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0448|cit448","unstructured":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of risperidone extended-release injectable suspension (TV-46000) for subcutaneous use as maintenance treatment in adult and adolescent patients with schizophrenia https:\/\/clinicaltrials.gov"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0449|cit449","unstructured":"Clinical trial evaluating the efficacy, safety and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in patients with schizophrenia https:\/\/clinicaltrials.gov"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0450|cit450","unstructured":"A study to test if TV-46000 is safe for maintenance treatment of schizophrenia https:\/\/clinicaltrials.gov"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0451|cit451","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0453|cit453","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD008016.pub3-BIB0455|cit455","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0920-9964(02)00355-9","article-title":"Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL","volume":"63","author":"Auquier","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0456|cit456","volume-title":"Chemotherapy in Psychiatry: Principles and Practice","author":"Baldessarini","year":"1985"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0458|cit458","volume-title":"Psychische Erkrankungen. Klinik und Therapie","author":"Berger","year":"2003"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0460|cit460","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0461|cit461","unstructured":"Comprehensive Meta-analysis Version 2 Borenstein M Hedges LV Higgins JP Rothstein H Biostat 2006"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2010.05.019","article-title":"The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia","volume":"121","author":"Boyer","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1600-0447.2007.01108.x","article-title":"Social functioning as an outcome measure in schizophrenia studies","volume":"116","author":"Burns","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the antipsychotic drugs","volume":"11","author":"Davis","year":"1974","journal-title":"Journal of Psychiatric Research"},{"issue":"12","key":"10.1002\/14651858.CD008016.pub3-BIB0466|cit466","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1176\/ajp.132.12.1237","article-title":"Overview: maintenance therapy in psychiatry: I. Schizophrenia","volume":"132","author":"Davis","year":"1975","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0467|cit467","first-page":"1591","volume-title":"Comprehensive Textbook of Psychiatry","author":"Davis","year":"1989"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0468|cit468","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0470|cit470","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0471|cit471","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub3-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub3-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","article-title":"Neuroleptic withdrawal in schizophrenic patients. A review of the literature","volume":"52","author":"Gilbert","year":"1995","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1185\/03007990903482772","article-title":"Practical guidance or dosing and switching paliperidone palmitate treatment in patients with schizophrenia","volume":"26","author":"Gopal","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0481|cit481","volume-title":"ECDEU Assessment Manual for Psychopharmacology-revised 1976. Washington, DC: DHEW","author":"Guy","year":"1976"},{"issue":"7414","key":"10.1002\/14651858.CD008016.pub3-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0483|cit483","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1185\/03007999909113374","article-title":"Patient satisfaction with, and acceptability of, atypical antipsychotics","volume":"15","author":"Kalali","year":"1999","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0485|cit485","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0486|cit486","volume-title":"Positive And Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1017\/S0033291700046377","article-title":"A self-rating scale of distress","volume":"3","author":"Kellner","year":"1973","journal-title":"Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1017\/S0033291718001393","article-title":"Effect of discontinuation vs maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis","volume":"49","author":"Kishi","year":"2019","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0489|cit489","doi-asserted-by":"crossref","unstructured":"Kishimoto T Robenzadeh A Leucht C Leucht S Watanabe K Mimura M Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials Schizophrenia Bulletin 2014 40 1 192 213","DOI":"10.1093\/schbul\/sbs150"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0490|cit490","volume-title":"Diagnosis and Drug Treatment of Psychiatric Disorders","author":"Klein","year":"1969"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomised controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomised, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD008016.pub3-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"9896","key":"10.1002\/14651858.CD008016.pub3-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"951962","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment? A review","volume":"39","author":"Marwaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality.","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","article-title":"Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse","volume":"114","author":"Moncrieff","year":"2006","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1176\/appi.ajp.161.9.1692","article-title":"Safety reporting in randomised trials of mental health interventions","volume":"161","author":"Papanikolaou","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0509|cit509","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","article-title":"Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used","volume":"197","author":"Pope","year":"2010","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0510|cit510","unstructured":"Foundation for Statistical Computing R: A language and environment for statistical computing R Core Team 2018"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0513|cit513","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/swra\/19.3.9","article-title":"SLOF: a behavioural rating scale for assessing the mentally ill","volume":"19","author":"Schneider","journal-title":"Social Work Research & Abstracts"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub3-BIB0515|cit515","first-page":"40","article-title":"Meta: an R package for meta-analyses","volume":"7","year":"2007","journal-title":"R News"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0516|cit516","first-page":"1228","article-title":"A Children's Global Assessment Scale (CGAS)","volume":"40","author":"Shaffer","year":"1983","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0517|cit517","first-page":"151","volume-title":"The Anxiety Disease and How to Overcome it","author":"Sheenan","year":"1983"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0518|cit518","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis","volume":"4","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0520|cit520","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0521|cit521","unstructured":"Intercooled Stata 7.0 for Windows Stata Corporation 2002"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0523|cit523","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD008016.pub3-BIB0524|cit524","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","article-title":"Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients","volume":"118","author":"Vernon","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0525|cit525","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archpsyc.1997.01830130055011","article-title":"Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment","volume":"54","author":"Viguera","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"00","key":"10.1002\/14651858.CD008016.pub3-BIB0526|cit526","first-page":"1","article-title":"Recovery from schizophrenia: is it possible?","volume":"31","author":"Vita","year":"2018","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub3-BIB0527|cit527","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059","article-title":"Clozapine vs typical neuroleptic medication for schizophrenia","author":"Wahlbeck","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1192\/bjp.180.6.490","article-title":"Violence and schizophrenia: examining the evidence","volume":"180","author":"Walsh","year":"2002","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0529|cit529","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","article-title":"Influence of antipsychotics on mortality in schizophrenia: systematic review","volume":"113","author":"Weinmann","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.177.1.42","article-title":"Self-report quality of life measure for people with schizophrenia: the SQLS","volume":"177","author":"Wilkinson","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008016.pub3-BIB0531|cit531","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub3-BIB0532|cit532","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/bjpo.bp.115.002576","article-title":"Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials","volume":"2","author":"Zhao","year":"2016","journal-title":"BJPsych Open"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0533|cit533","unstructured":"Bergman H Davies S Dawson S Kakourou A Spineli L Targeted update of Maintenance treatment with antipsychotic drugs for schizophrenia The Cochrane Collaboration, Targeted Updates Project 2016 https:\/\/community.cochrane.org\/news\/targeted-updates-project-case-study-b"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub3-BIB0534|cit534","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub3-BIB0535|cit535","doi-asserted-by":"crossref","unstructured":"Leucht S Tardy M Komossa K Heres S Kissling W Salanti G Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: systematic review and meta-analysis Lancet 2012 379 9831 2063 71","DOI":"10.1016\/S0140-6736(12)60239-6"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub3-BIB0536|cit536","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub2","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T01:11:57Z","timestamp":1669597917000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008016.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":536,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008016.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]}}}